OTCPK:TDSG.F

Stock Analysis Report

Executive Summary

Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Telo Genomics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

72.1%

TDSG.F

3.4%

US Healthcare Services

3.4%

US Market


1 Year Return

-51.9%

TDSG.F

13.4%

US Healthcare Services

5.4%

US Market

Return vs Industry: TDSG.F underperformed the US Healthcare Services industry which returned 13.4% over the past year.

Return vs Market: TDSG.F underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

TDSG.FIndustryMarket
7 Day72.1%3.4%3.4%
30 Day131.7%-0.2%-1.0%
90 Day-12.4%-6.2%-0.4%
1 Year-51.9%-51.9%13.6%13.4%7.7%5.4%
3 Yearn/a58.1%57.6%46.2%36.8%
5 Yearn/a53.1%52.0%65.6%47.5%

Price Volatility Vs. Market

How volatile is Telo Genomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Telo Genomics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Telo Genomics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Telo Genomics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of TDSG.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Telo Genomics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Telo Genomics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.4%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Telo Genomics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of TDSG.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Telo Genomics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Telo Genomics performed over the past 5 years?

-11.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TDSG.F is unprofitable, and losses have increased over the past 5 years at a rate of -11.8% per year.

Accelerating Growth: Unable to compare TDSG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TDSG.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: TDSG.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: TDSG.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TDSG.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Telo Genomics's financial position?


Financial Position Analysis

Short Term Liabilities: TDSG.F has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: TDSG.F has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: TDSG.F has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: TDSG.F's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: TDSG.F has a high level of physical assets or inventory.

Debt Coverage by Assets: TDSG.F has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TDSG.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TDSG.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.9% each year.


Next Steps

Dividend

What is Telo Genomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate TDSG.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TDSG.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TDSG.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TDSG.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TDSG.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Telo Genomics's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average board tenure


CEO

Sherif Louis 0

1.1yrs

Tenure

0

Dr. Sherif Louis, PhD, MSc, PMP, has been Chief Executive Officer of 3D Signatures Inc. since September 25, 2018. Dr. Louis served as Director of Clinical Operations and Manager of Patents & Grant at 3D Si ...


Board Age and Tenure

2.9yrs

Average Tenure

58yo

Average Age

Experienced Board: TDSG.F's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Sabine Mai

    Co-Founder

    • Tenure: 2.9yrs
    • Compensation: CA$16.00k
  • Sherif Louis

    Chief Executive Officer

    • Tenure: 1.1yrs
  • Ryan Cheung

    CFO & Director

    • Tenure: 1.1yrs

Board Members

  • Ian C. Smith

    Member of Clinical & Scientific Advisory Board

    • Tenure: 2.8yrs
  • Jonathan Goodman (50yo)

    Member of Business Advisory Board

    • Tenure: 3yrs
  • Ken Anderson (68yo)

    Member of Clinical & Scientific Advisory Board

    • Tenure: 2.9yrs
  • Heiner Dreismann (66yo)

    Member of Business Advisory Board

    • Tenure: 3yrs
  • Laurence Klotz

    Member of Clinical & Scientific Advisory Board

    • Tenure: 2.9yrs
  • John Lindsay

    Member of Business Advisory Board

    • Tenure: 3yrs
  • Hugh Rogers (39yo)

    Chairman of the Board

    • Tenure: 1.1yrs
  • Ferenc Somogyvari

    Member of Clinical & Scientific Advisory Board

    • Tenure: 2.4yrs
    • Compensation: CA$132.13k
  • Sabine Mai

    Co-Founder

    • Tenure: 2.9yrs
    • Compensation: CA$16.00k
  • Ryan Cheung

    CFO & Director

    • Tenure: 1.1yrs

Company Information

Telo Genomics Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Telo Genomics Corp.
  • Ticker: TDSG.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: CA$1.331m
  • Listing Market Cap: CA$1.008m
  • Shares outstanding: 66.53m
  • Website: https://www.telodx.com

Number of Employees


Location

  • Telo Genomics Corp.
  • MaRS Centre
  • South Tower
  • Toronto
  • Ontario
  • M5G 1L7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TELOTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 2016
3D0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 2016
TDSG.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 2016

Biography

Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products. Its proprietary software platform predicts the course of certain ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:48
End of Day Share Price2019/10/15 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.